OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press51810.17650/1818-8346-2022-17-1-43-52HEMATOLOGIC MALIGNANCIES: TREATMENTЛЕЧЕНИЕ ГЕМОБЛАСТОЗОВAdvances and perspective of the immunotherapy for relapsed/refractory multiple myeloma (interview)Достижения иперспективы иммунотерапии рецидивирующей/рефрактерной множественной миеломы (интервью)SemochkinS. V.СемочкинС. В.Russian Federation
Sergey V. Semochkin
3 2nd Botkinskiy Proezd, Moscow 125284,
1 Ostrovityanova St., Moscow 117997
Сергей Вячеславович Семочкин
125284 Москва, 2-й Боткинский проезд, 3,
117997 Москва, ул. Островитянова, 1
semochkin_sv@rsmu.ruР.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of RussiaМосковский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России2901202217143522901202229012022https://oncohematology.abvpress.ru/ongm/article/view/518
.
.
Mendeleeva L.P., Savchenko V.G., Parovichnikova L.P. et al. Analysis of transplantation activity in the Russian Federation for 2018 (report of the interregional register). Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2020;65(S1):180. (In Russ.)Менделеева Л.П., Савченко В.Г., Паровичникова Е.Н. и др. Анализ трансплантационной активности в РФ за 2018 г. (отчет межрегионального регистра). Гематология и трансфузиология 2020;65(S1):180.Semochkin S. V. Treatment of doublerefractory multiple myeloma. Onkogematologiya = Oncohematology 2021;16(3): 58–73. (In Russ.). DOI: 10.17650/18188346-2021-16-3-58-73.Семочкин С.В. Терапия рецидивирующей и рефрактерной множественной миеломы, отягощенной двойной рефрактерностью (обзор литературы). Онкогематология 2021;16(3):58–73. DOI: 10.17650/18188346-2021-16-3-58-73.Kim C., Braunlin M., Mehta B., Payne R. Outcomes of triple-class (proteasome inhibitor, immunomodulator, cd38 monoclonal antibody) exposed relapsed or refractory multiple myeloma (RRMM) in United States (US) real-world practice. Blood 2021;138(Suppl 1):3042. DOI: 10.1182/blood-2021-145588.Semochkin S.V. Biological fundamentals of application of immunomodulatory agents in treatment of multiple myeloma. Onkogematologiya = Oncohematology 2010;(1):21–31. (In Russ.)Семочкин С.В. Биологические основы применения иммуномодулирующих препаратов в лечении множественной миеломы. Онкогематология 2010;(1): 21–31.Dimopoulos M., Leleu X., Palumbo A. et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 2014;28(8):1573–85. DOI: 10.1038/leu.2014.60.Ludwig H., Boccadoro M., Moreau P. et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2021;35(1):31–44. DOI: 10.1038/s41375-020-01016-0.Dechow T., Aldaoud A., Behlendorf T. et al. Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: final results of the noninterventional study POSEIDON and comparison with the pivotal phase 3 clinical trials. Eur J Haematol 2022;108(2): 133–44. DOI: 10.1111/ejh.13719.Lacy M.Q., Hayman S.R., Gertz M.A. et al. Pomalidomide (CC4047) plus lowdose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27(3):5008–14. DOI: 10.1200/JCO.2009.23.6802.Lacy M.Q., Hayman S.R., Gertz M.A. et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010;24(11):1934–99. DOI: 10.1038/leu.2010.190.Lacy M.Q., Allred J.B., Gertz M.A. et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dualrefractory disease. Blood 2011;118(11):2970–5. DOI: 10.1182/blood-2011-04-348896.Kastritis E., Roussou M., Gavriatopoulou M. et al. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. Blood Adv 2019;3(23):4095–103. DOI: 10.1182/bloodadvances.2019000539.Hogan K.A., Chini C.C.S., Chini E.N. The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases. Front Immunol 2019;10:1187. DOI: 10.3389/fimmu.2019.01187.Van de Donk N. Immunomodulatory effects of CD38-targeting antibodies. Immunol Lett 2018;199:16–22. DOI: 10.1016/j.imlet.2018.04.005.Campbell K.S., Cohen A.D., Pazina T. Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma. Front Immunol 2018;9:2551. DOI: 10.3389/fimmu.2018.02551.Mateos M.V., Sonneveld P., Hungria V. et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: threeyear follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020;20(8): 509–18. DOI: 10.1016/j.clml.2019.09.623.Bahlis N.J., Dimopoulos M.A., White D.J. et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 2020;34(7):1875–84. DOI: 10.1038/s41375-020-0711-6.Dimopoulos M., Quach H., Mateos M.V., et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 2020;396(10245):186–97. DOI: 10.1016/S0140-6736(20)30734-0.Dimopoulos M.A., Terpos E., Boccadoro M. et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(6):801–12. DOI: 10.1016/S1470-2045(21)00128-5.Moreau P., Dimopoulos M.A., Yong K. et al. Isatuximab plus carfilzomib/ dexamethasone versus carfilzomib/ dexamethasone in patients with relapsed/ refractory multiple myeloma: IKEMA Phase III study design. Future Oncol 2020;16(2):4347–58. DOI: 10.2217/fon-2019-0431.Attal M., Richardson P.G., Rajkumar S.V. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019;394(10214):2096–107. DOI: 10.1016/S0140-6736(19)32556-5.Dimopoulos M.A., Lonial S., White D. et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 2020;10(9):91. DOI: 10.1038/s41408-020-00357-4.Dimopoulos M.A., Dytfeld D., Grosicki S. et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. Engl J Med 2018;379(19):1811–22. DOI: 10.1056/NEJMoa1805762.Shah N., Chari A., Scott E. et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 2020;34(4):985–1005. DOI: 10.1038/s41375-020-0734-z.Novak A.J., Darce J.R., Arendt B.K. et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004;103(2):689–94. DOI: 10.1182/blood-2003-06-2043.Pont M.J., Hill T., Cole G.O. et al. Gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood 2019;134(19):1585–97. DOI: 10.1182/blood.2019000050.Jew S., Chang T., Bujarski S. et al. Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment. Br J Haematol 2021;192(2): 272–80. DOI: 10.1111/bjh.16752.Lonial S., Lee H.C., Badros A. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21(2):207–21. DOI: 10.1016/S1470-2045(19)30788-0.Cohen A.D., Raje N., Fowler J.A. et al. How to train your T cells: overcoming immune dysfunction in multiple myeloma. Clin Cancer Res 2020;26(7):1541–54. DOI: 10.1158/1078-0432.CCR-19-2111.Lejeune M., Köse M.C., Duray E. et al. Bispecific, T-cell-recruiting antibodies in B-cell malignancies. Front Immunol 2020; 11:762. DOI: 10.3389/fimmu.2020.00762.Moreau P., Usmani S.Z., Garfall A.L. et al. Updated results from MajesTEC-1: phase 1/2 study of Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed/refractory multiple myeloma. Blood 2021;138(S1):896. DOI: 10.1182/blood-2021-147915.Harrison S.J., Minnema M.C., Lee H.C. et al. A Phase 1 First in Human (FIH) study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM). Blood 2020;136(S1):28–9. DOI: 10.1182/blood-2020-134063.Kumar S., D’Souza A., Shah N. et al. A phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-Cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. Blood 2021;138(Suppl 1):900. DOI: 10.1182/blood-2021-150757.Pillarisetti K., Edavettal S., Mendonça M. et al. A T-cell-redirecting bispecific Gprotein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 2020;135(15):1232–43. DOI: 10.1182/blood.2019003342.Krishnan A.Y., Monique C., Minnema M.C. et al. Updated Phase 1 results from MonumenTAL-1: first-in-human study of Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. Blood 2021;138(S1):158. DOI: 10.1182/blood-2021-146868.Cohen A.C., Harrison S.J., Krishnan A. et al. Initial clinical activity and safety of BFCR4350A, a FcRH5/CD3 T-Cellengaging bispecific antibody, in relapsed/ refractory multiple myeloma. Blood 2020;136(S1):42–3. DOI: 10.1182/blood-2020-136985.Munshi N.C., Anderson L.D. Shah N. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384(8):705–16. DOI: 10.1056/NEJMoa2024850.Martin T., Usmani S.Z., Berdeja J.G. et al. Updated results from CARTITUDE-1: PHASE 1B/2STUDY of Ciltacabtagene Autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Blood 2021:138(S1):549. DOI: 10.1182/blood-2021-146060.Zhang L., Jin G., Chen Z. et al. Lenalidomide improves the antitumor activity of CAR-T cells directed toward the intracellular Wilms Tumor 1 antigen. Hematology 2021;26(1):818–26. DOI: 10.1080/16078454.2021.1981534.Martín-Rojas R.M., Gómez-Centurión I., Bailén R. et al. Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel. Clin Case Rep 2022;10(1):e05209. DOI: 10.1002/ccr3.5209.Möhn N., Bonda V., Grote-Levi L. et al. Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. Neurol Res Pract 2022;4(1):1. DOI: 10.1186/s42466-021-00166-5.